Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome.
Pérez de Llano L, Dacal Rivas D, Marina Malanda N, Plaza Moral V, Gullón Blanco JA, Muñoz-Esquerre M, García-Moguel I, Díaz Campos RM, Martínez-Moragón E, Harbenau Mena A, Cosío BG, Padilla Galo A, Cisneros Serrano C. Pérez de Llano L, et al. J Asthma Allergy. 2022 Mar 18;15:363-369. doi: 10.2147/JAA.S338467. eCollection 2022. J Asthma Allergy. 2022. PMID: 35330786 Free PMC article.
Factors associated with suboptimal response to monoclonal antibodies in severe asthma.
Pérez de Llano L, Marina Malanda N, Urrutia I, Martínez-Moragón E, Gullón-Blanco JA, Díaz-Campos R, Esquerre MM, Mena AH, Cosío BG, Cisneros C, Polo FJL, Laorden D, Dacal Rivas D. Pérez de Llano L, et al. Allergy. 2023 Aug;78(8):2305-2310. doi: 10.1111/all.15693. Epub 2023 Mar 18. Allergy. 2023. PMID: 36866939 No abstract available.
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S, Barranco P, Marina Malanda N, Andrés LP, Alvarez-Gutiérrez FJ. Pérez de Llano LA, et al. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2277-2283.e2. doi: 10.1016/j.jaip.2019.01.017. Epub 2019 Jan 21. J Allergy Clin Immunol Pract. 2019. PMID: 30677539 Free article. Clinical Trial.
Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score.
Pérez de Llano L, Dávila I, Martínez-Moragón E, Domínguez-Ortega J, Almonacid C, Colás C, García-Rivero JL, Carmona L, García de Yébenes MJ, Cosío BG; FEOS Study Group. Pérez de Llano L, et al. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2725-2731. doi: 10.1016/j.jaip.2021.01.033. Epub 2021 Feb 4. J Allergy Clin Immunol Pract. 2021. PMID: 33549843
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data.
Pérez de Llano LA, Cosío BG, Lobato Astiárraga I, Soto Campos G, Tejedor Alonso MÁ, Marina Malanda N, Padilla Galo A, Urrutia Landa I, Michel de la Rosa FJ, García-Moguel I; Reslizumab Real-Life Spanish Group. Pérez de Llano LA, et al. J Asthma Allergy. 2022 Jan 14;15:79-88. doi: 10.2147/JAA.S340562. eCollection 2022. J Asthma Allergy. 2022. PMID: 35058696 Free PMC article.
A Simple Score for Future Risk Prediction in Patients with Controlled Asthma Who Undergo a Guidelines-Based Step-Down Strategy.
Pérez de Llano L, García-Rivero JL, Urrutia I, Martínez-Moragón E, Ramos J, Cebollero P, Carballada F, Blanco-Aparicio M, Vennera MDC, Merino M, Torralba-García Y, Plaza V. Pérez de Llano L, et al. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1214-1221.e3. doi: 10.1016/j.jaip.2018.10.017. Epub 2018 Oct 25. J Allergy Clin Immunol Pract. 2019. PMID: 30368006
Distilling Fact from the Vapor of Nuance: Asthma Exacerbations.
Pérez de Llano L, Dacal-Rivas D, Blanco-Cid N, Martín-Robles I. Pérez de Llano L, et al. J Allergy Clin Immunol Pract. 2021 Feb;9(2):842-843. doi: 10.1016/j.jaip.2020.10.007. J Allergy Clin Immunol Pract. 2021. PMID: 33551042 No abstract available.
159 results